<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522104</url>
  </required_header>
  <id_info>
    <org_study_id>SIK-FR 14-1</org_study_id>
    <nct_id>NCT02522104</nct_id>
  </id_info>
  <brief_title>Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)</brief_title>
  <official_title>Evaluation of the Impact of Renal Function on the Pharmacokinetics of Hydroxyurea (SIKLOS ®) in Normal-renal Function, Hyperfiltrating and Renal Failure Sickle Cell Disease Patients (DARH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADDMEDICA SASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADDMEDICA SASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of hydroxyurea in sickle cell disease patients with glomerular hyperfiltration and&#xD;
      renal failure requires a specific monitoring and dose adjustment in order to remain within&#xD;
      the therapeutic interval while limiting the risk of toxicity or therapeutic failure. For this&#xD;
      reason the investigators propose to compare the pharmacokinetic parameters of hydroxyurea in&#xD;
      normal-renal function sickle cell patients to those of patients with glomerular&#xD;
      hyperfiltration or moderate renal failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2015</start_date>
  <completion_date type="Actual">November 28, 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Plasmatic Data: Maximum Concentration (Cmax)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Plasmatic Data: Minimum Concentration (Cmin)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Plasmatic Data: Time to Obtain the Maximum Concentration (Tmax)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Plasmatic Data: Area Under the Curve (AUC0-24)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Plasmatic Data: Elimination Half-life (T½)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Plasmatic Data: Total Clearance (Cl Tot)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Plasmatic Data: Distribution Volume</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Urinary Data: Hydroxyurea Urinary Fractions</measure>
    <time_frame>From 0 to 4 hours, 4 to 7.5 hours and 7.5 to 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Urinary Data: Renal Clearance (Cl Renal).</measure>
    <time_frame>From 0 to 4 hours, 4 to 7.5 hours and 7.5 to 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Renal Function Disorder</condition>
  <arm_group>
    <arm_group_label>Normal-renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glomerular hyperfiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glomerular renal hyperfiltration: GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Siklos</intervention_name>
    <arm_group_label>Glomerular hyperfiltration</arm_group_label>
    <arm_group_label>Moderate renal failure</arm_group_label>
    <arm_group_label>Normal-renal function</arm_group_label>
    <other_name>hydroxyurea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Sickle cell disease (SS or S-β0thal) confirmed by haemoglobin electrophoresis and&#xD;
             genotyping by deoxyribonucleic acid (DNA) analysis.&#xD;
&#xD;
          -  Affiliation to a social security system.&#xD;
&#xD;
          -  Having freely consented in writing after being informed of the objective, programme&#xD;
             and potential risks incurred.&#xD;
&#xD;
        These criteria will apply to the 3 groups of sickle cell disease patients according to the&#xD;
        renal function stage defined by the glomerular filtration rate (GFR) estimated by the&#xD;
        formula of the Chronic Kidney Disease EPIdemiology (CKD EPI) collaboration without ethnic&#xD;
        criterion during the last 6 months before inclusion:&#xD;
&#xD;
          -  Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in&#xD;
             men.&#xD;
&#xD;
          -  Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2.&#xD;
&#xD;
          -  Glomerular renal hyperfiltration: GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140&#xD;
             mL/min/1.73m2 in men.&#xD;
&#xD;
               -  Treated with hydroxyurea (Siklos®) with a stable dosage for at least one week ± 2&#xD;
                  days before inclusion in the study and dose administered in the morning at 9:00 ±&#xD;
                  15 minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to consent.&#xD;
&#xD;
          -  Patients that do not comply.&#xD;
&#xD;
          -  Occurrence of vaso-occlusive crisis in the month prior to the inclusion in the study.&#xD;
&#xD;
          -  Patients having had an exchange transfusion in the 15 days before inclusion in the&#xD;
             study.&#xD;
&#xD;
          -  Patients participating in another clinical trial or in the exclusion period of a&#xD;
             previous clinical trial.&#xD;
&#xD;
          -  Patients treated with a diuretic.&#xD;
&#xD;
          -  Dialysis patient.&#xD;
&#xD;
          -  Patients with an intercurrent disorder, especially inflammatory, that has not&#xD;
             recovered for at least one month.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Patients deprived of liberty or under legal protection.&#xD;
&#xD;
          -  Patients who cannot understand the objective and the course of the study, incapable of&#xD;
             giving their consent.&#xD;
&#xD;
          -  In the event of severe hepatic failure.&#xD;
&#xD;
          -  In the event of severe renal failure (creatinine clearance &lt; 30 ml/min).&#xD;
&#xD;
          -  Patients who show toxic signs of bone marrow suppression.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BARTOLUCCI Pablo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri-Mondor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri-Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <results_first_submitted>August 3, 2021</results_first_submitted>
  <results_first_submitted_qc>August 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2021</results_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics of Hydroxyurea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal-renal Function</title>
          <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
        </group>
        <group group_id="P2">
          <title>Glomerular Hyperfiltration</title>
          <description>Patients with glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men</description>
        </group>
        <group group_id="P3">
          <title>Moderate Renal Failure</title>
          <description>Patients with moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal-renal Function</title>
          <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
        </group>
        <group group_id="B2">
          <title>Glomerular Hyperfiltration</title>
          <description>Patients with glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
        </group>
        <group group_id="B3">
          <title>Moderate Renal Failure</title>
          <description>Patients with moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="4.8"/>
                    <measurement group_id="B2" value="27.8" spread="7.6"/>
                    <measurement group_id="B3" value="50.0" spread="7.5"/>
                    <measurement group_id="B4" value="33.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure of Plasmatic Data: Maximum Concentration (Cmax)</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Plasmatic Data: Maximum Concentration (Cmax)</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Micromolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.8" spread="164.4"/>
                    <measurement group_id="O2" value="316.8" spread="73.9"/>
                    <measurement group_id="O3" value="260.2" spread="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Plasmatic Data: Minimum Concentration (Cmin)</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Plasmatic Data: Minimum Concentration (Cmin)</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Micromolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="2.38"/>
                    <measurement group_id="O2" value="4.2" spread="2.2"/>
                    <measurement group_id="O3" value="7.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Plasmatic Data: Time to Obtain the Maximum Concentration (Tmax)</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Plasmatic Data: Time to Obtain the Maximum Concentration (Tmax)</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.7"/>
                    <measurement group_id="O2" value="1.0" spread="0.9"/>
                    <measurement group_id="O3" value="1.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Plasmatic Data: Area Under the Curve (AUC0-24)</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Plasmatic Data: Area Under the Curve (AUC0-24)</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Hour x Micromolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1144.0" spread="364.1"/>
                    <measurement group_id="O2" value="1384.3" spread="266.5"/>
                    <measurement group_id="O3" value="1580.6" spread="540.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Plasmatic Data: Elimination Half-life (T½)</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Plasmatic Data: Elimination Half-life (T½)</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="0.57"/>
                    <measurement group_id="O2" value="4.75" spread="0.92"/>
                    <measurement group_id="O3" value="4.98" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Plasmatic Data: Total Clearance (Cl Tot)</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with Glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with Moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Plasmatic Data: Total Clearance (Cl Tot)</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Liter/Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="4.1"/>
                    <measurement group_id="O2" value="10.3" spread="1.9"/>
                    <measurement group_id="O3" value="6.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Plasmatic Data: Distribution Volume</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with Normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with Glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with Moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Plasmatic Data: Distribution Volume</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" spread="20.3"/>
                    <measurement group_id="O2" value="70.3" spread="16.2"/>
                    <measurement group_id="O3" value="44.2" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Urinary Data: Hydroxyurea Urinary Fractions</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>From 0 to 4 hours, 4 to 7.5 hours and 7.5 to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with Normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with Glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with Moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Urinary Data: Hydroxyurea Urinary Fractions</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Percentage urinary excretion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="10.2"/>
                    <measurement group_id="O2" value="44.3" spread="9.6"/>
                    <measurement group_id="O3" value="20.2" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Urinary Data: Renal Clearance (Cl Renal).</title>
        <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
        <time_frame>From 0 to 4 hours, 4 to 7.5 hours and 7.5 to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-renal Function</title>
            <description>Patients with Normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
          </group>
          <group group_id="O2">
            <title>Glomerular Hyperfiltration</title>
            <description>Patients with Glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Failure</title>
            <description>Patients with Moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Urinary Data: Renal Clearance (Cl Renal).</title>
          <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
          <units>Liter/Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.6"/>
                    <measurement group_id="O2" value="4.7" spread="1.3"/>
                    <measurement group_id="O3" value="1.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the signature of the informed consent form by the patient until 7 days after the end of the follow-up for the study. Duration of participation for each patients : 9 to 40 days depending on the concomitant treatments.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal-renal Function</title>
          <description>Patients with normal-renal function defined by 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
        </group>
        <group group_id="E2">
          <title>Glomerular Hyperfiltration</title>
          <description>Patients with glomerular renal hyperfiltration defined by GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
        </group>
        <group group_id="E3">
          <title>Moderate Renal Failure</title>
          <description>Patients with moderate renal failure defined by 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Aplastic anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vaso-occlusive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical director</name_or_title>
      <organization>Addmedica</organization>
      <phone>+33 1 72 69 01 86</phone>
      <email>corinne.duguet@addmedica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

